Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome

Kidney Int. 2021 Aug;100(2):265-268. doi: 10.1016/j.kint.2021.02.033. Epub 2021 Mar 3.
No abstract available

Keywords: TMA; aHUS; atypical hemolytic uremic syndrome; complement; eculizumab.

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Atypical Hemolytic Uremic Syndrome* / diagnosis
  • Atypical Hemolytic Uremic Syndrome* / drug therapy
  • Complement Inactivating Agents
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • eculizumab